Blossom Health has secured a $20 million seed and Series A funding round to develop an AI copilot for psychiatry, with the goal of scaling high-quality mental health care nationwide.

CEO note: the new funding will accelerate Blossom Health’s mission by advancing innovative technology to make psychiatric services more effective and accessible.

Investment will bolster an AI-powered platform that assists clinicians with personalized mental health treatments, aiming to improve diagnostic accuracy and patient outcomes.

The platform seeks to transform episodic care into continuous clinician-patient relationships, with many patients seen within 48 hours or the same day, supported by input from a large clinical team.

Founder Zhao stresses clinician buy-in as essential and outlines plans to expand beyond nine states, deepen payer relationships, and continue AI R&D to improve care delivery.

The initiative targets the US psychiatric workforce shortage, addressing long wait times and vast areas without mental health professionals.

AI copilots are expected to reduce clinicians’ administrative burdens while providing real-time insights and decision support to enhance the therapeutic experience.

Clinical buy-in is central; Blossom involves clinicians in AI development and maintains a large clinical team for pilots before broader rollout.

Funds will expand geographic reach, strengthen payor relationships, onboard more providers, and fuel further AI capability development.

Blossom positions itself as a scalable infrastructure layer for modern mental healthcare, aiming for rapid patient access and streamlined operations.

The platform already serves hundreds of clinicians and over 10,000 patients across multiple states, with in-network coverage from major insurers and average patient copays around $22.

Blossom’s platform automates administrative tasks via AI agents, while clinical copilots assist with evaluation, diagnosis refinement, and medication selection, preserving psychiatrists’ clinical authority.